Key result
Amiodarone pulmonary toxicity has protean features, and neither foamy alveolar macrophages nor lamellated inclusions reliably distinguish toxic from nontoxic patients.
Why the study?
Do specific pathologic or radiographic features reliably distinguish amiodarone pulmonary toxicity from non-toxic amiodarone use?
Population
20 patients taking amiodarone (15 with amiodarone pulmonary toxicity and 5 without evidence of toxic effect)
Comparison
Amiodarone therapy resulting in pulmonary toxicity vs Amiodarone therapy without pulmonary toxicity
Design
Case-control
Authors
Loading...
Clinicians should not rely on these findings to diagnose amiodarone toxicity; leaves open the need for validated distinguishing criteria.
Case-Control (n=20)
Do specific pathologic or radiographic features reliably distinguish amiodarone pulmonary toxicity from non-toxic amiodarone use?
Pathologic findings such as foamy alveolar macrophages and lamellated cytoplasmic inclusions are common in patients taking amiodarone but do not reliably distinguish those with pulmonary toxicity from those without.
John I. Kennedy (1987) conducted a case-control in Amiodarone pulmonary toxicity (n=20). Amiodarone pulmonary toxicity vs. Amiodarone patients without evidence of toxic effect was evaluated on Pathologic features (foamy alveolar macrophages and lamellated inclusion bodies). Amiodarone pulmonary toxicity has protean features, and neither foamy alveolar macrophages nor lamellated inclusions reliably distinguish toxic from nontoxic patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: